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Abstract
Background: Dengue is a mosquito-borne viral infection which has been estimated to cause a global economic
burden of US$8.9 billion per year. 40% of this estimate was due to what are known as productivity costs (the costs
associated with productivity loss from both paid and unpaid work that results from illness, treatment or premature
death). Although productivity costs account for a significant proportion of the estimated economic burden of
dengue, the methods used to calculate them are often very variable within health economic studies. The aim of
this review was to systematically examine the current estimates of the productivity costs associated with dengue
episodes in Asia and to increase awareness surrounding how productivity costs are estimated.
Method: We searched PubMed and Web of Knowledge without date and language restrictions using terms related
to dengue and cost and economics burden. The titles and abstracts of publications related to Asia were screened
to identify relevant studies. The reported productivity losses and costs of non-fatal and fatal dengue episodes were
then described and compared. Costs were adjusted for inflation to 2017 prices.
Results: We reviewed 33 relevant articles, of which 20 studies reported the productivity losses, and 31 studies reported
productivity costs. The productivity costs varied between US$6.7–1445.9 and US$3.8–1332 for hospitalized and
outpatient non-fatal episodes, respectively. The productivity cost associated with fatal dengue episodes varied between
US$12,035-1,453,237. A large degree of this variation was due to the range of different countries being investigated
and their corresponding economic status. However, estimates for a given country still showed notable variation.
Conclusion: We found that the estimated productivity costs associated with dengue episodes in Asia are notable.
However, owing to the significant variation in methodology and approaches applied, the reported productivity costs of
dengue episodes were often not directly comparable across studies. More consistent and transparent methodology
regarding the estimation of productivity costs would help the estimates of the economic burden of dengue be more
accurate and comparable across studies.
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Background
Dengue is a widespread mosquito-borne viral disease, with
over 40% (2.5 billion people) of the world’s population at
risk of infection [1]. The incidence of dengue has in-
creased 30-fold over the past 50 years, and between 2005
and 2015 the number of dengue-related deaths increased
by nearly 50% (from 12,300 to 18,400 deaths annually) [1,
2]. Recently, it was estimated that there were 58.4 million
symptomatic dengue cases and 13,586 dengue-related
deaths in 2013 [3, 4]. These numbers corresponded to an
estimated total cost of illness of US$8.9 billion (2013
prices) [4]. Of this total estimated cost of illness, US$3.77
billion (42%) resulted from productivity costs [5]. Product-
ivity costs (also known as indirect costs) are defined as the
costs associated with the loss of paid and unpaid work that
result from illness, treatment, disability or premature
death [6] i.e. they are the monetary value of productivity
losses (lost productive time). These can occur from the
patients themselves as well as their informal caregivers.
However, although productivity costs accounted for a sig-
nificant proportion of the estimated economic burden of
dengue, the methods used to calculate them are inconsist-
ent across studies (Fig. 1 and Additional file 1). This is not
unique to dengue; it is a general problem across the health
economics research field [7]. The accurate estimation of
productivity costs is important to understand the true eco-
nomic burden of dengue.
The aim of this review is to systematically examine the
current estimates of the productivity costs associated
with dengue episodes in Asia, and to gain a more com-
prehensive understanding regarding the variation in the
methodology used to calculate these costs. We also dis-
cuss more generally many of the areas of debate sur-
rounding the quantification of productivity costs, how
Fig. 1 An overview of the methods to value productivity costs
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productivity costs can be applied within cost-effectiveness
analyses, and make recommendations for future research.
These findings will help improve future research and
consistency regarding the quantification and reporting of
dengue-related productivity costs. This will be helpful for
developing more accurate estimates of the economic burden
of dengue as well as helping policymakers and healthcare
funders in decision making regarding dengue interventions.
Methods
We searched for relevant articles using the PubMed and
Web of Science electronic databases using variants of
the following keywords (dengue, dengue virus, dengue
hemorrhagic fever, dengue fever, dengue infection,
DENV, DENV-1, DENV-2, DENV-3, DENV-4, econom-
ics, cost, cost analysis, cost of illness, health care cost,
and cost-effectiveness) on 24th of April 2019, without
any date or language restrictions. The search terms were
discussed and tested by two reviewers (TMH and HCT).
A detail information of search terms and PRISMA
checklist were provided in Additional file 2. The titles
and abstracts of all the articles were scanned to identify
relevant studies by a single reviewer (TMH). The bibli-
ographies of related papers were also searched to find
additional articles not originally retrieved from the data-
bases. The studies related to the Asia region were
screened for manually. Full texts of the identified studies
were then reviewed for eligibility by a reviewer (TMH)
and articles without reported productivity losses or costs
were excluded. Any studies with uncertainty regarding
their inclusion were discussed and resolved by two re-
viewers (TMH and HCT). The full selection process is
outlined in Fig. 2.
One key feature of dengue is the variety of types and
definitions of dengue episodes. Many studies focus im-
plicitly on episodes managed in the formal health care
Fig. 2 Decision tree outlining the inclusion and exclusion of the identified studies. Several ‘grey literature’ texts which were not found within the
databases were also identified using Google Scholar and the bibliographies of other papers. A PRISMA checklist is provided in Additional file 2
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system, while episodes managed outside the formal
healthcare system were commonly excluded [4]. In some
non-health economic studies, “cases” also include non-
symptomatic dengue infections. Accordingly, in this re-
view, we refer only to symptomatic dengue episodes. Esti-
mates related to the productivity losses and costs of both
non-fatal and fatal dengue episodes were extracted. Where
feasible, we also reported the estimated productivity losses
and costs associated with the patients’ informal caregivers.
When possible, we stratified the results according to the
severity of the dengue episode (such as dengue fever, se-
vere or non-severe dengue, dengue hemorrhagic fever and
dengue shock syndrome) and the source of care (out-
patient versus hospitalized). Notably, the World Health
Organization (WHO) classification for dengue has been
updated from dengue fever or dengue hemorrhagic fever
to dengue or severe dengue [8]. We reported the estimates
in the same way as in the source paper.
Throughout this paper, productivity losses were de-
fined as the estimated amount of productive time (i.e.
paid or unpaid work) lost due to a dengue episode.
Productivity costs were defined as the monetary value of
these productivity losses.
As the studies were performed in different years, it
was necessary to adjust for inflation to make the esti-
mates more directly comparable. We therefore adjusted
the reported productivity costs to 2017 US prices. For
the majority of the studies, the reported productivity
costs were converted to their country’s currency and ad-
justed for inflation using the specific country’s Gross
Domestic Product (GDP) deflator rates from the Inter-
national Monetary Fund and then reconverted to US$
using the 2017 exchange rate [9–11]. Further detail is
provided in the Additional file 2.
Results
We identified 56 potentially relevant articles reporting
the cost of dengue illness in Asian countries. Of these,
23 of the studies only reported direct costs and were
therefore excluded. The remaining 33 studies were in-
cluded in the analysis and reviewed in further detail. De-
tails of the identified articles are described below
(Tables 1 and 2). Generally, the majority of the studies
(83%) focused on countries in Southeast Asia that are
considered to be highly endemic. Moreover, the majority
of the studies (64%) were published within the last
10 years. A notable gap in the literature was the rela-
tively few studies performed in India and China.
There was substantial variation regarding how the dif-
ferent studies defined and estimated productivity losses
and productivity costs. For instance, some studies only
considered the productivity losses of the patients, while
others also accounted for the losses experienced by the
patients’ informal caregivers (Additional file 2 Table S1).
There was also notable variation in how the studies
placed monetary values on productivity losses, i.e. how
they estimated the productivity costs. Many studies did
not collect primary data and based their estimates on
secondary or aggregated data, particularly for the prod-
uctivity costs relating to premature mortality.
In the following sections we summarize:
1) The reported productivity losses (i.e. the productive
time lost) associated with non-fatal dengue episodes
and their informal caregivers.
2) The estimated productivity costs associated with
non-fatal episodes i.e. the monetary value of the
productivity losses.
3) The estimated productivity costs related to fatal
dengue episodes.
4) How these estimated productivity costs of dengue
episodes influence estimates of dengue’s total
economic burden.
5) How these productivity costs can be incorporated
into cost-effectiveness analyses of dengue
interventions.
The reported productivity losses related to non-fatal
dengue episodes
Patients’ productivity losses (productive time lost)
A number of studies reported the productivity losses as-
sociated with dengue episodes (Additional file 2 Table
S1). The majority of the studies collected this data via
interviews with patients and/or their caregivers. The
average reported number of days loss from a dengue epi-
sode occurring in a child ranged between 3.9–11.4 days
for hospitalized episodes and 0.7–4.3 days for outpatient
episodes. Similarly, the reported number of days loss
from a dengue episode occurring in an adult ranged
from 5 to 31.9 days for hospitalized episodes and 4.0–7.2
for outpatient episodes. However, there were differences
in the way the different studies estimated and reported
productivity losses, particularly in children (Additional
file 2 Table S1), which made a formal comparison of the
different studies difficult. For instance, to estimate the
productivity losses for children, the studies varied with
some using the number of school days they had missed,
the duration of the illness [35, 42], the number of work
days loss by their informal caregivers [22, 34, 41] or a
combination of factors [15, 17, 21]. However, the dur-
ation of illness does not necessarily equal the number of
school days loss (such as if a child is ill over a weekend).
In addition, the time that informal caregivers spent look-
ing after sick children can be substantial [13, 18], and
thus this also needs to be accounted for to fully capture
the productivity losses of dengue episodes occurring in
children.
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Table 1 The estimated productivity costs of non-fatal dengue episodes
Authors Countries Wage source Caregiver’s productivity
costs included
Average productivity cost related to a
non-fatal dengue episode (US$ 2017
prices)
Hospitalized episodes
Clark et al. [12] Thailand Unclear Yes 37.5
Huy et al. [13] Cambodia From survey Yes 14.1
Mia et al. [14] Malaysia Minimum wage Yes 276.5
Okanurak et al. [15] Thailand Minimum wage of two different cities Yes Adult patient: 54.3
Child patient: 64.5
Suaya et al. [16] Cambodia Minimum wage Yes 85.9
Thailand Minimum wage Yes 67.9
Malaysia Minimum wage Yes 143.0
Kongsin et al. [17] Thailand Minimum wage Yes 68.4
Suaya et al. [18] Cambodia Minimum wage Yes Average: 85.2
Plasma leakage case: 91.4
Non-plasma leakage case: 65.1




Tam et al. [20] Vietnam From survey NA 64.7
Pham et al. [21] Vietnam From survey NA 51.3








Suaya et al. [23] Cambodia Unclear Yes 30.4
Harving et al. [24] Vietnam From survey Yes 24.2
Shepard et al. [25] Malaysia Estimation NA 196.0
Lee et al. [26] Vietnam From survey Yes 58.0
Thailand From survey Yes 46.4
Bhavsar et al. [27] India From survey and minimum wage Yes 155.1
Tran et al. [28] Vietnam GDP per capita and from survey Yes 75.7








Tran et al. [30] Vietnam From survey Yes Median: 88.1





Zeng et al. [32] Indonesia GDP per capita NA 60.4
Malaysia GDP per capita NA 181.7
Philippines GDP per capita NA 41.9
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Table 1 The estimated productivity costs of non-fatal dengue episodes (Continued)
Authors Countries Wage source Caregiver’s productivity
costs included
Average productivity cost related to a
non-fatal dengue episode (US$ 2017
prices)
Thailand GDP per capita NA 50.9
Vietnam GDP per capita NA 15.4
Shepard et al. [33] Bhutan GDP per capita NA 37.3
Brunei GDP per capita NA 615.8
Cambodia GDP per capita NA 39.1
East Timor GDP per capita NA 9.6
Indonesia GDP per capita NA 48.0
Laos GDP per capita NA 20.5
Malaysia GDP per capita NA 198.6
Myanmara GDP per capita NA 11.9
Philippines GDP per capita NA 42.5
Singapore GDP per capita NA 1445.9
Thailand GDP per capita NA 54.6
Vietnam GDP per capita NA 10.7
Shepard et al. [4] Afghanistan GDP per capita NA 6.7
Bangladesh GDP per capita NA 13.7
Bhutan GDP per capita NA 39.7
Brunei GDP per capita NA 927.7
Cambodia GDP per capita NA 38.1
China GDP per capita NA 127.3
India GDP per capita NA 19.5
Indonesia GDP per capita NA 52.3
Lao GDP per capita NA 22.8
Malaysia GDP per capita NA 168
Maldives GDP per capita NA 141.3
Myanmar GDP per capita NA 12.1
Nepal GDP per capita NA 8.1
Pakistan GDP per capita NA 19
Philippines GDP per capita NA 38.2
Singapore GDP per capita NA 911.6
Srilanka GDP per capita NA 51.2
Taiwan GDP per capita NA 1318.4
Tajikistan GDP per capita NA 7.6
Thailand GDP per capita NA 50.7
East Timor GDP per capita NA 74.9
Uzbekistan GDP per capita NA 10.2
Vietnam GDP per capita NA 13.2
Yemen GDP per capita NA 31.6
Nadjib et al. [34] Indonesia From survey and minimum wage Yes 45.0–130.2
Lee et al. [35] Cambodia From survey Yes 59.9
Bangert et al. [36] Maldives Unclear NA 134.4
Outpatient episodes
Shepard et al. [25] Malaysia Minimum wage NA 172.5
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Table 1 The estimated productivity costs of non-fatal dengue episodes (Continued)
Authors Countries Wage source Caregiver’s productivity
costs included
Average productivity cost related to a
non-fatal dengue episode (US$ 2017
prices)





Average wage Caregiver only Overall average: 65.8
Lee et al. [26] Vietnam From survey Yes 23.4
Thailand From survey Yes 27.7
Suaya et al. [16] Cambodia Minimum wage NA NA
Thailand Minimum wage Yes 125.2
Malaysia Minimum wage NA NA
Zeng et al. [32] Indonesia GDP per capita NA 33.4
Malaysia GDP per capita NA 159.6
Philippines GDP per capita NA 22.8
Thailand GDP per capita NA 12.5
Vietnam GDP per capita NA 11.3
Tran et al. [30] Vietnam From survey Yes Median: 44.1
Shepard et al. [33] Bhutan GDP per capita NA 17.5
Brunei GDP per capita NA 288.7
Cambodia GDP per capita NA 5.6
East Timor GDP per capita NA 4.5
Indonesia GDP per capita NA 22.5
Laos GDP per capita NA 9.6
Malaysia GDP per capita NA 173.8
Myanmara GDP per capita NA 5.6
Philippines GDP per capita NA 19.9
Singapore GDP per capita NA 1332.1
Thailand GDP per capita NA 13.7
Vietnam GDP per capita NA 8.4
Shepard et al. [4] Afghanistan GDP per capita NA 3.8
Bangladesh GDP per capita NA 7.5
Bhutan GDP per capita NA 21.5
Brunei GDP per capita NA 519.7
Cambodia GDP per capita NA 5.6
China GDP per capita NA 71.8
India GDP per capita NA 11.3
Indonesia GDP per capita NA 29.4
Lao GDP per capita NA 12.5
Malaysia GDP per capita NA 146.8
Maldives GDP per capita NA 79.4
Myanmar GDP per capita NA 6.9
Nepal GDP per capita NA 4.6
Pakistan GDP per capita NA 10.7
Philippines GDP per capita NA 21.8
Singapore GDP per capita NA 839.4
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All of the studies quantified productivity losses relating
to absenteeism (someone not attending work). However,
none of the studies appeared to explicitly quantify the
productivity losses relating to presenteeism. Presentee-
ism is likely to be present at every phase of the illness. It
is probable that presenteeism is even more significant in
low and lower-middle-income countries, as the patients
will be less likely to have access to paid “sick days” and
many would not be able to afford to take much time
off work. Studies on arthritis and mental health have
found that presenteeism accounted for the majority of
their associated total productivity losses [43–45].
Compared to long-term chronic illnesses, the impact
of presenteeism will likely be less extreme for dengue,
however it should be considered and evaluated further
in future studies.
The patients’ productivity losses were found to corres-
pond to the severity of the dengue episode. Three studies
differentiated the productive time lost based on disease se-
verity [17, 22, 41]. For example, Nguyen et al. [22] found
that adult patients lost on average 8.4, 9.7 and 12.3 work
days with dengue fever, dengue hemorrhagic fever, and
dengue shock syndrome cases, respectively. Lee et al. [26]
also found that the number of sick days reported before
and after study enrollment were significantly related to
the severity of illness.
The majority of studies focused implicitly on episodes
managed within the formal health system. Although this is
understandable, this focus excludes episodes that cause
productivity losses but do not receive a formal diagnosis
or management in the formal health care system.
Four studies reported the patients’ productivity losses
pre, during and post-hospitalization period [12, 20, 21, 46].
They ranged from 1.8–6.25 days for pre-hospitalization
period, 3.5–6.76 days for hospitalization period and 1.2–
18.89 days for post-hospitalization period (Fig. 3). This
demonstrates the importance of also quantifying the prod-
uctivity losses experienced pre- and post-hospitalization. It
is noteworthy that the productivity losses estimated by Rafi-
que et al. [46] were much larger than the other studies, par-
ticularly those experienced post-hospitalization. The
authors stated that this difference could be potentially due
to patients experiencing fatigue post-infection [46, 47].
Within the literature, there is variation regarding the re-
ported proportion of cases (2–68%) experiencing post-
acute consequences of dengue infection (such as fatigue,
asthenia and trouble working), as well as the reported dur-
ation of these symptoms [48]. The majority of the studies
we identified within this review would not have a long
enough follow-up period to fully capture the potential im-
pact of these post-acute consequences on the estimated
productivity losses of dengue. The incidence, duration and
Table 1 The estimated productivity costs of non-fatal dengue episodes (Continued)
Authors Countries Wage source Caregiver’s productivity
costs included
Average productivity cost related to a
non-fatal dengue episode (US$ 2017
prices)
Srilanka GDP per capita NA 28.5
Taiwan GDP per capita NA 739
Tajikistan GDP per capita NA 4.4
Thailand GDP per capita NA 12.4
East Timor GDP per capita NA 41.8
Uzbekistan GDP per capita NA 5.5
Vietnam GDP per capita NA 10.2
Yemen GDP per capita NA 18.3
Nadjib et al. [34] Indonesia From survey and minimum wage Yes 8.1–24.6
Bangert et al. [36] Maldives Unclear NA 75.5
Unspecified setting
Luh et al. [41]α Taiwan GDP per capita NA The average annual productivity cost per case
Epidemic year: 176.4
Non-epidemic year: 169.3
Carrasco et al. [37] Singapore GDP per capita NA HCA: 1669.8–3198.9
FCA: 1247.3–2281.7
Hariharan et al. [38] India GNI per capita NA 12.7
Where possible the costs were adjusted to US$ 2017 prices (see Additional file 2). In some cases, the adjusted costs were smaller than the original values reported
due to changes in the country’s US$ exchange rate
IS International dollars, NA not available, GDP gross domestic product, HCA human capital approach, FCA friction cost approach, GNI gross national income, DF
dengue fever, DHF dengue hemorrhagic fever, DSS dengue shock syndrome
a: US GDP deflators were used to adjust for inflation (see Additional file 2)
α: Values were not adjusted for inflation (see Additional file 2)
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Table 2 The estimated average productivity costs related to fatal dengue episodes
Authors Country Method Wage source Discount rate Average productivity cost related to a
fatal dengue episode (US$ 2017 prices)
Okanurak et al. [15] Thailand NA GNP per capita NA Children: 166,861
Adult: 167,209
Suaya et al. [16] Cambodia NA GDP per capita 3% 15,568
Thailand NA GDP per capita 99,339
Malaysia NA GDP per capita 132,074
Shim et al. [39] Philippines HCA GDP per capita 3% Children: 85,218
Adults: 55,392
Carrasco et al. [37] Singapore HCA and
FCA
HCA used GDP per capita, FCA




Shepard et al. [25] Malaysia HCA Minimum wage 3% 52,168.9
Beaute et al. [40] Cambodia HCA Average annual income from World
Bank
3% 16,242.1
Luh et al.α [41] Taiwan HCA GDP per capita 3% Epidemic year: 224,884.4
Non-epidemic year: 215,634.7
Shepard et al. [4] Afghanistan HCA GDP per capita 3% Children: 18,077
Adult: 12,368
Bangladesh HCA GDP per capita 3% Children: 34,772
Adult: 22,354
Bhutan HCA GDP per capita 3% Children: 77,077
Adult: 49,873
Brunei HCA GDP per capita 3% Children: 851,115
Adult: 554,098
Cambodia HCA GDP per capita 3% Children: 32,483
Adult: 21,282
China HCA GDP per capita 3% Children: 187,606
Adult: 122,518
India HCA GDP per capita 3% Children: 44,120
Adult: 28,729
Indonesia HCA GDP per capita 3% Children: 91,835
Adult: 59,693
Lao HCA GDP per capita 3% Children: 49,823
Adult: 32,178
Malaysia HCA GDP per capita 3% Children: 238,657
Adult: 155,441
Maldives HCA GDP per capita 3% Children: 208,713
Adult: 135,881
Myanmar HCA GDP per capita 3% Children: 28,443
Adult: 18,962
Nepal HCA GDP per capita 3% Children: 23,007
Adult: 14,955
Pakistan HCA GDP per capita 3% Children: 43,947
Adult: 28,506
Philippines HCA GDP per capita 3% Children: 72,754
Adult: 47,290
Singapore HCA GDP per capita 3% Children: 1,453,237
Adult: 948,121
Sri Lanka HCA GDP per capita 3% Children: 93,487
Adult: 61,013
Taiwan HCA GDP per capita 3% Children: 1,199,795
Adult: 783,068
Tajikistan HCA GDP per capita 3% Children: 19,002
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severity of these post-acute consequences is a key area of
uncertainty regarding the burden of dengue [49]. Cur-
rently, the majority of studies in this area are from Latin
America, and more research is needed from other settings
(particularly higher transmission settings, where the age of
distribution of episodes differs) [49].
Unpaid informal caregivers’ productivity losses (productive
time lost)
Many dengue patients require support from informal
caregivers: individuals (often family members) who pro-
vide unpaid assistance and support while the patient is ill.
Within the studies we identified, the average number of
days lost by the patients’ informal caregivers ranged be-
tween 1.0–25.5 days for hospitalized episodes and 0.1–2
days for outpatient episodes (Additional file 2 Table S1).
The number of days informal caregivers spent looking
after patients did not necessarily equal their number of
work days loss. For instance, Huy et al. [13] reported that
informal caregivers spent on average 11.4 days looking
after a dengue patient, whilst on average, they lost 8.3
work days. Only capturing the number of work days loss
might underestimate the actual productivity losses of in-
formal caregivers. For example, some informal caregivers
Table 2 The estimated average productivity costs related to fatal dengue episodes (Continued)
Authors Country Method Wage source Discount rate Average productivity cost related to a
fatal dengue episode (US$ 2017 prices)
Adult: 12,035
Thailand HCA GDP per capita 3% Children: 159,870
Adult: 104,347
East Timor HCA GDP per capita 3% Children: 121,101
Adult: 79,282
Uzbekistan HCA GDP per capita 3% Children: 21,256
Adult: 13,777
Vietnam HCA GDP per capita 3% Children: 55,848
Adult: 36,555




India NA NA NA 33,185.4
Bangert et al. [36] Maldives NA NA NA Children: 198,181.3
Adult: 129,024.3
Where possible, the costs were adjusted to US$ 2017 prices. In some cases, the adjusted costs were smaller than the original values reported due to changes in
the country’s US$ exchange rate
α: Values were not adjusted for inflation (see Additional file 2)
Human capital and friction cost approaches are defined in Fig. 1
GNP Gross national product, GDP gross domestic product, HCA human capital approach, FCA friction cost approach, NA not available
Fig. 3 The average number of days lost by patients over the whole course of a dengue episode. Clark et al. [12], Pham et al. [21], Rafique et al.
[46], Tam et al. [20]. It should be noted only these papers were included as they were the only ones that reported the days lost stratified in this way
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may not be working (such as students or retirees). This
highlights the importance of also considering lost unpaid
work when estimating productivity losses.
As with the estimated productivity losses of the pa-
tients, the productivity losses of the informal caregivers
corresponded to the severity of the episode [18, 22]. For
instance, Suaya et al. [18] reported that families of chil-
dren with plasma leakage (a marker of more severe den-
gue) lost on average five days more than those without
plasma leakage (15.2 versus 10.5 days). Similarly, Nguyen
and Luong [22] reported that informal caregivers lost an
average of 7.3, 7.1 and 9.9 days for dengue fever, dengue
hemorrhagic fever and dengue shock syndrome cases,
respectively.
In some instances, multiple caregivers will support a
single dengue patient. However, only a few studies re-
ported the actual number of informal caregivers that
were supporting the dengue patients [12, 22, 41, 46]. If
this is not accounted for, the productivity losses of infor-
mal caregivers could be underestimated. Future studies
should therefore clearly state the number of informal
caregivers and their assumptions when calculating these
productivity losses.
It was not always clear if studies were quantifying the
productivity losses experienced by informal caregivers
across the full duration of the dengue episodes or just
period that the patient is hospitalized/at the outpatient
clinic. If the former was done, the total productivity
losses experienced by dengue patients’ informal care-
givers could have been underestimated in some studies.
The estimated productivity costs related to non-fatal
dengue episodes
In order to estimate the productivity costs associated
with dengue episodes, a monetary value is placed on the
corresponding productivity losses (i.e. number of days
loss) discussed previously. The estimated productivity
costs from the different studies are summarized in
Table 1. However, owing to the variety and inconsist-
ency in the methods applied to calculate the productivity
costs, it was difficult to directly compare the estimates.
Accordingly, the estimated productivity costs associated
with dengue episodes varied widely across the different
studies. Specifically, the average estimated productivity
costs of a hospitalized episode ranged from US$6.7–
1445.9 (2017 prices) and the average estimated product-
ivity cost of an outpatient episode ranged from US$3.8–
1332 (2017 prices) (Table 1). A large degree of this vari-
ation was due to the range of different countries being
investigated and their corresponding economic status.
Unsurprisingly, there was a positive relationship between
the estimated productivity cost and the country’s GDP
(Fig. 4). However, estimates for a given country still
showed notable variation (Additional file 2 Figure S1).
This was likely largely due to differences in method-
ology, such as the wage sources used to value productiv-
ity losses and whether or not the productivity losses of
informal caregivers were included.
The methods for placing a monetary value on product-
ivity losses can vary depending on whether the loss is ex-
perienced by an adult patient, a child patient or an
informal caregiver. These issues are discussed more in
the following subsections.
Valuing monetarily an adult’s productivity losses
(estimating productivity costs)
The productivity losses incurred by adult dengue pa-
tients are typically valued based on a specified wage
source(s), which reflects the average income of the
population at risk of disease in the study setting. Many
of the identified studies used a minimum wage for this
[14–19, 25, 27]. However, the minimum wage does not
always reflect the actual average income of the whole
population (Fig. 5). Furthermore, there is currently no
definitive evidence that dengue is strongly associated
with poverty [61, 62]. Accordingly, using the minimum
wage for valuing monetarily dengue-related productivity
losses could lead to an underestimation of the corre-
sponding productivity costs. The extent of this will vary
depending on the study setting (Fig. 5).
Currently, there is no standard method for estimating
productivity costs. This has resulted in variation across
different studies, even when they are reporting to have
used the same approach; this is true not just for dengue
but for the health economics field in general [7]. For ex-
ample, some countries have different types of minimum
wage (such as Vietnam, where it varies across different
regions and the Philippines where it varies for different
types of occupation). However, studies often do not
clearly state specifically what minimum wage they are
using and its source. In addition, variations in how wage
sources are converted/modified for the purposes of the
study can have a significant impact (e.g., to estimate a
daily wage is the yearly wage rate divided by 365 days or
by the number of work days etc.).
A key area of debate in the health economic field is re-
garding the use of the human capital approach or the
friction cost approach (Fig. 1 and Additional file 1) and
the two approaches can lead to significantly different es-
timates of productivity costs [63]. However, for non-fatal
dengue episodes, it could be argued that there would
often be little difference between the two approaches, as
the typical duration of illness is shorter than the friction
period. Interestingly, despite the approach not always be-
ing stated directly, most of the studies appeared to have
used/applied the human capital approach to estimate the
productivity costs related to non-fatal and fatal dengue
episodes.
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Fig. 4 The reported average productivity costs in the identified studies. Costs are reported in 2017 prices
Fig. 5 The difference in some example potential wage sources commonly used to value productivity losses. Data sources: Minimum wage [50–58],
Gross National Income [59], and Gross Domestic Product [60]. Costs are reported in 2016 US$ prices
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The productivity costs of lost paid work were com-
monly quantified and reported across the studies. How-
ever, those related to lost unpaid work were often
ignored. Specifically, some studies did not value the
productivity losses of unemployed patients, students or
individuals not earning money at the time of the survey
(such as farmers). It should be acknowledged that quan-
tifying monetarily unpaid productivity losses is challen-
ging, and the correct methodology is debatable. Though
there are some recommendations [64], there are no spe-
cific guidelines on how to measure and value unpaid
productivity losses within cost of illness studies. More
research and development of guidelines are urgently
needed to inform practice in this area [65].
Valuing monetarily children’s productivity losses
Valuing monetarily the productivity losses of children is
challenging, and currently there is no broadly accepted
guideline or methodology for this [64, 66]. Because of
this, there was notable variation regarding how the prod-
uctivity costs relating to dengue episodes in children
were estimated. For example, Kongsin et al. [17] esti-
mated this productivity cost by multiplying the cost that
the government spends per day on a primary school stu-
dent and the number of school days loss, while other re-
searchers such as Okanurak et al. [15] and Nadjib et al.
[34] based the estimate on the productivity losses of the
children’s informal caregivers. It is noteworthy that some
studies reported the productivity losses of children with-
out quantifying the productivity costs and vice versa [15,
21]. Accordingly, further comparison across studies is
limited. Further research and guidelines are needed to
allow the productivity costs relating to children to be es-
timated more accurately and consistently. Some recom-
mendations to help with this area are outlined in
Table 3 and discussed further by Andronis et al. [67].
Valuing monetarily informal caregivers’ productivity losses
The time that informal caregivers spend caring for a pa-
tient is typically considered to be unpaid work. There-
fore, the opportunity cost method or replacement cost
method are generally used to quantify the productivity
losses of informal caregivers in monetary terms (Fig. 1).
The average reported productivity cost of informal care-
givers varied between US$7.1–99.4 per hospitalized den-
gue episode and US$2.1–16.2 per outpatient dengue
episode. It should be noted that some studies quantified
the productivity cost of informal caregivers but did not
report the specific economic loss relating to them (in-
stead, they reported the total productivity cost relating
to the dengue episode). Most of the studies appeared to
use the opportunity cost approach to value productivity
losses of informal caregivers.
The majority of the studies did not specifically report
informal caregivers who were teenagers or retirees.
Teenagers and retirees could conceivably spend a lot of
time caring for patients, though similar to children,
quantifying their productivity costs can be challenging
and the correct methodology to use is under debate [64,
68, 69].
More transparency is needed in future studies regard-
ing how the productivity costs related to patients’ infor-
mal caregivers are quantified.
The estimated productivity costs related to fatal dengue
episodes
We have discussed the estimated productivity costs asso-
ciated with acute non-fatal dengue episodes; however, a
small proportion of dengue patients die. Some studies
estimated the economic burden associated with these
fatal dengue episodes. The average estimated productiv-
ity costs related to a fatal episode varied across the dif-
ferent studies between US$15,568-1,453,237 for episodes
in children and US$12,035–948,121 for episodes in
adults (Table 2). This variation was partly due to the dif-
ferences in economic status of the countries investigated,
but also due to three main methodological factors/as-
sumptions: the assumed number of potential years of life
lost, the wage source and method applied to value the
years of life lost. These differences make it difficult to
directly compare the estimates from the different
Table 3 Research needs and recommendations for future
studies
Key research needs
More data quantifying the productivity losses over the full course of the
dengue episode.
More data quantifying the productivity losses associated with
presenteeism and lost unpaid work.
More data quantifying the productivity losses associated with post-acute
consequences.
Further investigation and data describing patents’ informal caregivers
and their productivity losses.
More data on the health and economic burden of dengue from India
and China.
Recommendations for future studies
Clearly state the losses and costs associated with lost paid work and
unpaid work.
Clearly report the period of disease that accounted for the productive
time lost (i.e. pre-hospitalization, hospitalization and post-
hospitalization).
Clearly state and justify the wage source(s) used to value the
productivity costs.
Report the average number of informal caregivers per dengue patient
and how their time was valued.
Clearly state and justify how children’s productivity losses are quantified
and valued monetarily.
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studies. To improve consistency, Shepard et al. [4] pro-
vided separate estimates for premature deaths in chil-
dren and adults. Due to the higher number of life years
lost by child deaths, their economic values were higher.
The method applied to calculate the number of poten-
tial years of productive life lost can influence the esti-
mated productivity costs related to fatal dengue
episodes. Different studies used different methods for
this [70]. For example, some estimated the potential
years of productive life lost based on life expectancy
whereas others used retirement age. The majority of
studies used the local life expectancy; however, this
might overestimate the productivity costs related to pre-
mature mortality (as the life expectancy will typically be
higher than the retirement age in that setting). Similarly,
there was variation in the working ages assumed across
studies and countries as productivity losses/costs were
quantified from different ages, such as age 15 [29, 40]
and age 21 [19]. The appropriate age will depend on the
study setting(s) but should be clearly stated and justified.
There was variation across the different studies regard-
ing which wage source was used to value potential years
of productive life lost (Table 2). The majority of studies
used the per capita GDP [4, 16, 37, 39, 41]. However,
the WHO’s cost-effectiveness analysis guide criticized
the use of per capita GDP in this way, stating that it
would overestimate the productivity costs [71]. Depend-
ing on the wage source used, the productivity costs
could easily be overestimated or underestimated (Fig. 5).
Thus, the wage source employed should be carefully ex-
amined such that it appropriately reflects the monetary
value of the productivity of the specific population at
risk of dengue within the investigated setting(s).
Finally, whether the human capital approach or fric-
tion cost approach was used influences the productivity
costs related to premature mortality (Fig. 1 and Add-
itional file 1). The estimated productivity cost related to
fatal dengue episodes were notably lower when the fric-
tion cost approach was used (Table 2). The debate re-
garding which method is more appropriate is ongoing
(Additional file 1). However, even when studies stated
that they used the same approach, owing to the variation
in the methods outlined above, the results could still be
significantly different. Although the friction cost method
was proposed as an alternative to the human capital ap-
proach [63], the human capital approach was still more
commonly used within the field [63].
Discussion
We found that the estimated productivity costs associ-
ated with dengue episodes in Asia are notable. However,
due to the significant variation in methodology and ap-
proaches applied, the reported productivity costs were
often not directly comparable across studies.
In the future, greater consistency regarding how the
productivity costs related to dengue are calculated would
be invaluable and make different studies more compar-
able. This will be important for estimates of the total
economic burden of dengue and within economic evalu-
ations of dengue interventions.
The total economic burden associated with productivity
costs
We have reviewed the productivity costs associated with
individual dengue episodes. It is important to note that
the total economic burden associated with dengue-
related productivity costs will also depend on the inci-
dence of symptomatic dengue episodes. The Global Bur-
den of Disease (GBD) 2017 study estimated that there
were 86,183,620 symptomatic dengue episodes in Asia in
2017 (95% uncertainty interval 51,918,388-131,567,619)
[72]. This number is significantly higher than the esti-
mate within the GBD 2013 study (46,059,323 episodes in
South Asia and Southeast Asia, East Asia and Oceania)
[4]. This highlights the variation in the estimates of the
incidence of dengue episodes and the need for this to be
considered when comparing the results of different stud-
ies. For example, the estimates of the total economic
burden of dengue in Vietnam have varied between
US$5.43–94.87 million (2016 prices) and this variation
was largely driven by the wide range in the assumed in-
cidence of symptomatic episodes (between 69,680-2,263,
880 symptomatic dengue episodes per year – based on a
range of sources/methods) [73]. This highlights that for
a good cost of illness estimates both good cost data and
epidemiology data are needed.
Using productivity costs within cost-effectiveness analysis
Productivity costs account for a significant proportion of
the economic burden of dengue [4]. Consequently, if
and how they are included within a dengue related cost-
effectiveness analysis could notably influence its
outcome.
Within cost-effectiveness analyses, there are effectively
two types of productivity costs (Fig. 6):
 Those corresponding to the productivity losses
directly associated with accessing the intervention
(e.g. someone takes a day off work to go to an
outpatient clinic to get a vaccine).
 Those corresponding to the averted productivity
losses that result from prevented morbidity/
mortality (i.e. disease case is prevented and
therefore, its related productivity costs that would
have otherwise occurred are averted). These averted
productivity losses are often referred to as
productivity gains.
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The productivity costs of dengue episodes discussed in
the previous sections of this paper could be used to quan-
tify the productivity costs associated with the productivity
gains that result from a dengue intervention within a cost-
effectiveness analysis (based on the number of episodes
averted by an intervention and their corresponding prod-
uctivity costs). Within the cost-effectiveness ratio, these
productivity costs associated with productivity gains are
effectively a negative cost (Fig. 6).
The recommendations for which productivity costs
should be included in cost-effectiveness analysis vary
(Fig. 6). The first United States (US) Panel on Cost-
Effectiveness in Health and Medicine (known as the Wash-
ington panel) recommended that the productivity costs re-
lated to the productivity losses associated with an
intervention should be included within the cost component
of the cost-effectiveness analysis [74]. However, they argued
that those related to the productivity gains associated with
prevented morbidity/mortality should not be, as they are
(at least partly) captured within the quality-adjusted life
year (QALY) effectiveness measure: therefore including
these productivity gains within the cost component of the
equation would potentially lead to double counting of the
effectiveness of the intervention [74]. However, this recom-
mendation has been challenged, with some arguing that the
QALY measure does not capture these productivity gains
[6, 75–79]. Recently, the second US Panel on Cost-
Effectiveness in Health and Medicine recommended that
both productivity losses and productivity gains should be
included in the cost component of the cost-effectiveness ra-
tio [64]. The debate in this area has heavily focused on the
use of QALYs, although it could be argued that there is still
a degree of double counting (albeit smaller) with the
disability-adjusted life year (DALY) measure.
The WHO’s cost-effectiveness analysis guide recom-
mends that the productivity costs associated with both
productivity losses and productivity gains should be ex-
cluded from a cost-effectiveness ratio [71]. The reason
given was that there is no “conceptually appropriate”
way of measuring these productivity changes in monet-
ary terms and that including productivity costs within
cost-effectiveness analyses would simply introduce noise
into the calculations. They suggested that when product-
ivity gains/losses are believed to be important, studies
should attempt to quantify them as rigorously as pos-
sible and report them separately.
Owing to the debate in this area within the health eco-
nomic field, and the significance of the dengue related
productivity costs, researchers performing cost-
effectiveness analyses of dengue interventions should
clearly state their assumptions regarding the method-
ology being applied and highlight the fact that the ap-
propriateness of certain methods is still under debate.
Limitations of this analysis
A potential source of bias in our search strategy is that it
did not capture studies published outside of the searched
electronic databases (i.e. grey literature such as policy
documents/reports, and many non-English language
publications etc.). For example, we found few articles
reporting the burden of dengue in China and India,
which may be due to studies relating to these countries
not being published in journals which are indexed in
PubMed or Web of Science. Efforts were made to
minimize this bias by searching Google Scholar, WHO’s
Dengue Bulletin and the bibliographies of selected stud-
ies. It should be noted that the selection process was not
performed independently by two researchers (i.e. not in
duplicate), which could result in selection bias. To miti-
gate this, the papers where there was uncertainty regard-
ing their inclusion were discussed between two
reviewers. Furthermore, because there is no standard
Fig. 6 Overview of the types of productivity costs included within cost-effectiveness analysis
Hung et al. BMC Infectious Diseases          (2020) 20:393 Page 15 of 18
methodology for conducting cost of illness studies, the
quality of the identified studies was not assessed. The
variation in quality could result in biases in the esti-
mated productivity costs of dengue episodes (potentially
resulting in either an over or underestimation). How-
ever, this observed variation further supports our pri-
mary finding regarding the need for greater consistency
in future studies.
Conclusion
A major impetus for calculating the cost of an illness
episode is to have a standard burden measure that can
be used for comparisons across countries and time pe-
riods, and for use within economic evaluation of inter-
ventions. Productivity costs can be a key component of
the cost of an illness dengue episode. We found that
the estimated productivity costs associated with
dengue episodes in Asia are notable. However, owing
to the significant variation in methodology and ap-
proaches applied, the reported productivity costs of
dengue episodes were often not directly comparable
across studies.
The majority of studies we identified only valued ab-
senteeism from paid work. The losses associated with
lost unpaid work and presenteeism have not been ad-
equately addressed or characterized. Further work is also
needed to account for the productivity costs incurred by
patients’ informal caregivers. Due to such losses not be-
ing fully captured, the productivity costs of dengue could
be underestimated.
In the future, further guidelines and recommendations
regarding how to calculate productivity costs would be
invaluable and make different studies more consistent
and comparable. What is most important moving for-
ward is that the assumptions and methods used to esti-
mate productivity costs are clearly reported.
More consistent and transparent methodology regard-
ing the estimation of productivity costs would help the
estimates of the economic burden of dengue be more ac-
curate and comparable across studies. Ultimately, accur-
ate estimates of the economic burden of dengue will be
crucial to informing policy in both the prevention and
treatment of this highly prevalent disease, particularly in
settings with limited resources.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12879-020-05109-0.
Additional file 1. Overview of the methods applied to calculate
productivity costs.
Additional file 2 Description of the adjustment for inflation, Table S1:
The estimated productivity losses of patients and their informal
caregivers, Figure S1: The average reported productivity costs as a
fraction of the study settings per capita GDP, The search terms and
PRISMA CHECKLIST.
Abbreviations
WHO: World Health Organization; GDP: Gross Domestic Product; GNP: Gross
National Product; GBD: Global Burden of Disease; US: United States;
QALY: Quality-adjusted life year; DALY: Disability-adjusted life year; GNI: Gross




TMH, HCT conceived the manuscript. TMH wrote the first draft of the
manuscript. DSS, AAB, HAN, AM, HEC HCT, helped draft the manuscript. All
authors read and approved the final manuscript.
Funding
The work was supported by the Wellcome Trust core grant [106680/Z/14/Z].
HCT is supported by joint funding by the UK Medical Research Council
(MRC) and the UK Department for International Development (DFID) under
the MRC/DFID Concordat agreement and is also part of the EDCTP2
programme supported by the European Union [MR/R015600/1].
Availability of data and materials
Not applicable.





DSS has received grant and other support from Takeda Pharmaceuticals and
Sanofi Pasteur. Neither support is related to nor funded by the present
paper.
Author details
1Oxford University Clinical Research Unit, Wellcome Trust Major Overseas
Programme, Ho Chi Minh City, Vietnam. 2Schneider Institutes for Health
Policy, Heller School, Brandeis University, Waltham, USA. 3London Centre for
Neglected Tropical Disease Research, London, UK. 4Department of Infectious
Disease Epidemiology, School of Public Health, Faculty of Medicine, St Marys
Campus, Imperial College London, Norfolk Place, London, UK. 5Department
of Global Health and Infection, Brighton and Sussex Medical School, Falmer,
Brighton, England. 6Centre for Tropical Medicine and Global Health, Nuffield
Department of Medicine, University of Oxford, Oxford, UK. 7Saw Swee Hock
School of Public Health, National University of Singapore, Singapore,
Singapore. 8MRC Centre for Global Infectious Disease Analysis, Department of
Infectious Disease Epidemiology, School of Public Health, Faculty of
Medicine, St Mary’s Campus, Imperial College London, Norfolk Place, London,
UK.
Received: 3 December 2019 Accepted: 20 May 2020
References
1. World Health Organization. Vector borne diseases 2016. Available from:
http://www.who.int/mediacentre/factsheets/fs387/en/index2.html.
2. Murray CJ, Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, et al. Global,
regional, and national life expectancy, all-cause mortality, and cause-specific
mortality for 249 causes of death, 1980–2015: a systematic analysis for the
global burden of disease study 2015. Lancet. 2016;388(10053):1459–544.
3. Stanaway JD, Shepard DS, Undurraga EA, Halasa YA, Coffeng LE, Brady OJ,
et al. The global burden of dengue: an analysis from the global burden of
disease study 2013. Lancet Infect Dis. 2016;16:712–23.
4. Shepard DS, Undurraga EA, Halasa YA, Stanaway JD. The global economic
burden of dengue: a systematic analysis. Lancet Infect Dis. 2016;16:935–41.
Hung et al. BMC Infectious Diseases          (2020) 20:393 Page 16 of 18
5. Koopmanschap MA, van Ineveld BM. Towards a new approach for
estimating indirect costs of disease. Soc Sci Med. 1992;34(9):1005–10.
6. Brouwer WB, Koopmanschap MA, Rutten FF. Productivity costs in cost-
effectiveness analysis: numerator or denominator: a further discussion.
Health Econ. 1997;6(5):511–4.
7. Krol M, Brouwer W, Rutten F. Productivity costs in economic evaluations:
past, present, future. Pharmacoeconomics. 2013;31:537–49.
8. World Health Organization. Dengue and Severe Dengue 2019. Available
from: https://www.who.int/news-room/fact-sheets/detail/dengue-and-
severe-dengue. [cited 2019 25 Nov].







10. World Bank. Official exchange rate 2018. Available from: https://data.
worldbank.org/indicator/PA.NUS.FCRF?end=2017&locations=AF-BD-BT-BN-
CN-KH-IN-ID-IR-JP-KR-LA-MY-MV-MM-NP-PK-PH-SG-UZ-VN&start=2013.
11. Turner HC, Lauer JA, Tran BX, Teerawattananon Y, Jit M. Adjusting for
Inflation and Currency Changes Within Health Economic Studies. Value
Health. 2019;22(9):1026-32.
12. Clark DV, Mammen MP Jr, Nisalak A, Puthimethee V, Endy TP. Economic
impact of dengue fever/dengue hemorrhagic fever in Thailand at the family
and population levels. Am J Trop Med Hyg. 2005;72(6):786–91.
13. Huy R, Wichmann O, Beatty M, Ngan C, Duong S, Margolis HS, et al. Cost of
dengue and other febrile illnesses to households in rural Cambodia: a
prospective community-based case-control study. BMC Public Health. 2009;9:155.
14. Mia MS, Begum RA, Er AC, Pereira JJ. Assessing the cost burden of dengue
infection to households in Seremban, Malaysia. Southeast Asian J Trop Med
Public Health. 2016;47(6):1167–76.
15. Okanurak K, Sornmani S, Indaratna K. The cost of dengue hemorrhagic fever
in Thailand. Southeast Asian J Trop Med Public Health. 1997;28(4):711–7.
16. Suaya JA, Shepard DS, Siqueira JB, Martelli CT, Lum LC, Tan LH, et al. Cost of
dengue cases in eight countries in the Americas and Asia: a prospective
study. Am J Trop Med Hyg. 2009;80(5):846–55.
17. Kongsin S, Jiamton S, Suaya JA, Vasanawathana S, Sirisuvan P, Shepard DS.
Cost of dengue in Thailand. Dengue Bull. 2010;34:77–88.
18. Suaya JA, Chantha N, Huy R, Sah BK, Moh-Seng C, Socheat D, et al. Clinical
characterization, diagnosis and socioeconomic impact of hospitalized
dengue in Cambodia. Dengue Bull. 2010;34:89–102.
19. Onuh W, Cabanacan-Salibay C, Manaig P. Economic costs and burden of
dengue disease in Cavite Province, Philippines. Sci Med. 2016;26(2):11.
20. Tam PT, Dat NT, Huu LM, Thi XCP, Duc HM, Tu TC, et al. High household
economic burden caused by hospitalization of patients with severe dengue fever
cases in Can Tho province, Vietnam. Am J Trop Med Hyg. 2012;87(3):554–8.
21. Pham LD, Tran NHP, Le NDT, Vo TQ. Economic report on the cost of
dengue fever in Vietnam: case of a provincial hospital. Clinicoecon
Outcomes Res. 2016;9:1–8.
22. Nguyen TKT, Luong CQ. Assessing the economic burden of dengue in
southern Viet Nam: results of a prospective multicenter cost study; 2011.
23. Suaya JA, Shepard DS, Chang MS, Caram M, Hoyer S, Socheat D, et al. Cost-
effectiveness of annual targeted larviciding campaigns in Cambodia against
the dengue vector Aedes aegypti. Tropical Med Int Health. 2007;12(9):1026–36.
24. Harving ML, Rönsholt FF. The economic impact of dengue hemorrhagic
fever on family level in southern Vietnam. Dan Med Bull. 2007;54(2):170–2.
25. Shepard DS, Undurraga EA, Lees RS, Halasa Y, Lum LC, Ng CW. Use of
multiple data sources to estimate the economic cost of dengue illness in
Malaysia. Am J Trop Med Hyg. 2012;87(5):796–805.
26. Lee JS, Mogasale V, Lim JK, Carabali M, Lee KS, Sirivichayakul C, et al. A
multi-country study of the economic burden of dengue fever: Vietnam,
Thailand, and Colombia. PLoS Negl Trop Dis. 2017;11(10):e0006037.
27. Bhavsar AT, Shepard DS, Suaya JA, Mafowosofo M, Hurley CL. A private
hospital-based study assessing knowledge, attitudes, practices and costs
associated with dengue illness in Surat. India Dengue Bull. 2010;34:54–64.
28. Tran NYN, Vo QT. The economic value of informal care for dengue patients
in Vietnam. Int J Res Ayurveda Pharm. 2016;7(6):101–6.
29. Tozan Y, Ratanawong P, Sewe MO, Wilder-Smith A, Kittayapong P.
Household costs of hospitalized dengue illness in semi-rural Thailand. PLoS
Negl Trop Dis. 2017;11(9):e0005961.
30. Tran BX, Thu GV, Hoang LN, Tuan ALN, Thanh TT, Thanh BN, et al. Cost-of-
Illness and the Health-Related Quality of Life of Patients in the Dengue
Fever Outbreak in Hanoi in 2017. Int J Environ Res Public Health. 2018;15(6):
1174.
31. El Fezzazi H, Branchu M, Carrasquilla G, Pitisuttithum P, Perroud AP, Frago C,
et al. Resource use and costs of dengue: analysis of data from phase III
efficacy studies of a tetravalent dengue vaccine. Am J Trop Med Hyg. 2017;
97(6):1898–903.
32. Zeng W, Halasa-Rappel YA, Baurin N, Coudeville L, Shepard DS. Cost-
effectiveness of dengue vaccination in ten endemic countries. Vaccine.
2018;36(3):413–20.
33. Shepard DS, Undurraga EA, Halasa YA. Economic and disease burden of
dengue in Southeast Asia. PLoS Negl Trop Dis. 2013;7:e2055.
34. Nadjib M, Setiawan E, Putri S, Nealon J, Beucher S, Hadinegoro SR, et al.
Economic burden of dengue in Indonesia. PLoS Negl Trop Dis. 2019;13(1):
e0007038.
35. Lee J-S, Mogasale V, Lim JK, Ly S, Lee KS, Sorn S, et al. A multi-country study
of the economic burden of dengue fever based on patient-specific field
surveys in Burkina Faso, Kenya, and Cambodia. PLoS Negl Trop Dis. 2019;
13(2):e0007164.
36. Bangert M, Latheef AT, Pant SD, Ahmed IN, Saleem S, Rafeeq FN, et al.
Economic analysis of dengue prevention and case management in the
Maldives. PLoS Negl Trop Dis. 2018;12(9):e0006796.
37. Carrasco LR, Lee LK, Lee VJ, Ooi EE, Shepard DS, Thein TL, et al. Economic
impact of dengue illness and the cost-effectiveness of future vaccination
programs in Singapore. PLoS Negl Trop Dis. 2011;5(12):e1426.
38. Hariharan D, Das MK, Shepard DS, Arora NK. Economic burden of dengue
illness in India from 2013 to 2016: A systematic analysis. Int J Infect Dis.
2019;84:S68-73.
39. Shim E. Dengue dynamics and vaccine cost-effectiveness analysis in the
Philippines. Am J Trop Med Hyg. 2016;95(5):1137–47.
40. Beaute J, Vong S. Cost and disease burden of dengue in Cambodia. BMC
Public Health. 2010;10:521.
41. Luh DL, Liu CC, Luo YR, Chen SC. Economic cost and burden of dengue
during epidemics and non-epidemic years in Taiwan. J Infect Public Health.
2017;11(2):215-23.
42. Anderson KB, Chunsuttiwat S, Nisalak A, Mammen MP, Libraty DH, Rothman
AL, et al. Burden of symptomatic dengue infection in children at primary
school in Thailand: a prospective study. Lancet. 2007;369(9571):1452–9.
43. Li X, Gignac MA, Anis AH. The indirect costs of arthritis resulting from
unemployment, reduced performance, and occupational changes while at
work. Med Care. 2006;44(4):304–10.
44. Burton WN, Chen C-Y, Conti DJ, Schultz AB, Pransky G, Edington DW. The
association of health risks with on-the-job productivity. J Occup Environ
Med. 2005;47(8):769–77.
45. Goetzel RZ, Long SR, Ozminkowski RJ, Hawkins K, Wang S, Lynch W. Health,
absence, disability, and presenteeism cost estimates of certain physical and
mental health conditions affecting US employers. J Occup Environ Med.
2004;46(4):398–412.
46. Rafique I, Nadeem Saqib MA, Munir MA, Qureshi H, Siddiqui S, Habibullah S,
et al. Economic burden of dengue in four major cities of Pakistan during
2011. J Pak Med Assoc. 2015;65(3):256–9.
47. Seet RC, Quek AM, Lim EC. Post-infectious fatigue syndrome in dengue
infection. J Clin Virol. 2007;38(1):1–6.
48. Tiga DC, Undurraga EA, Ramos-Castañeda J, Martínez-Vega RA, Tschampl
CA, Shepard DS. Persistent symptoms of dengue: estimates of the
incremental disease and economic burden in Mexico. Am J Trop Med Hyg.
2016;94(5):1085–98.
49. Hung TM, Wills B, Clapham HE, Yacoub S, Turner HC. The uncertainty
surrounding the burden of post-acute consequences of dengue infection.
Trends Parasitol. 2019;35(9):673–6.
50. WageIndicator. Minimum wage in Vietnam with effect from 01–01–2016 to
31-12-2016 2018. Available from: https://wageindicator.org/main/salary/
minimum-wage/vietnam/archive/2. [cited 2018 15 May].
51. WageIndicator. Minimum Wages in Cambodia with effect from 01–01–2016
to 31-12-2016 2018. Available from: https://wageindicator.org/main/salary/
minimum-wage/cambodia-1/archive/2. [cited 2018 15 May].
52. WageIndicator. Minimum wage in Delhi w.e.f April 1, 2016 to September 30,
2016 2018. Available from: https://paycheck.in/main/salary/minimumwages/
delhi/minimum-wage-in-delhi-w-e-f-april-1-2016-to-september-30-2016.
[cited 2018 15 May].
Hung et al. BMC Infectious Diseases          (2020) 20:393 Page 17 of 18
53. Trading economics. Malaysia Minimum Monthly Wages 2013-2018 2018.
Available from: https://tradingeconomics.com/malaysia/minimum-wages.
[cited 2018 15 May].
54. Trading economics. Thailand Minimum Daily Wage 1973-2018 2018. Available from:
https://tradingeconomics.com/thailand/minimum-wages. [cited 2018 18 May].
55. Minimum-wage. Philippines minimum wage rate 2018 2018. Available from:
https://www.minimum-wage.org/international/philippines. [cited 2018 18 May].
56. Trading economics. Taiwan Minimum Monthly Wage 2018. Available from:
https://tradingeconomics.com/taiwan/minimum-wages.
57. Varkkey B, Korde R, Singh S. minimum Wage Comparison: Asian Countries –
Minimum Wage Fixing; 2016.
58. The Manila Times. DOLE:Minimum salary of domestic workers in Brunei now
is USD 400 2015. Available from: https://www.manilatimes.net/2015/02/10/
news/latest-news/doleminimum-salary-of-domestic-workers-in-brunei-now-
is-usd-400/161903/.
59. World Bank. GNI per capita, Atlas method (Current US$) 2018. Available
from: https://data.worldbank.org/indicator/NY.GNP.PCAP.CD?locations=KH-
VN-TH-PH-IN-MY.
60. World Bank. GDP per capita (Current US$) 2018. Available from: https://data.
worldbank.org/indicator/NY.GDP.PCAP.CD?locations=MY-PH-TH-IN-VN-SG.
61. Mulligan K, Dixon J, Sinn C-LJ, Elliott SJ. Is dengue a disease of poverty? A
systematic review. Pathog Glob Health. 2015;109(1):10–8.
62. Teixeira MG, Barreto ML, Costa MCN, Ferreira LDA, Vasconcelos PF,
Cairncross S. Dynamics of dengue virus circulation: a silent epidemic in a
complex urban area. Tropical Med Int Health. 2002;7(9):757–62.
63. Koopmanschap MA, Rutten FF, van Ineveld BM, Van Roijen L. The friction
cost method for measuring indirect costs of disease. J Health Econ. 1995;
14(2):171–89.
64. Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG. Cost-
effectiveness in health and medicine, Second edn. New York: Oxford
University Press; 2016.
65. Verbooy K, Hoefman R, van Exel J, Brouwer W. Time is money: investigating
the value of leisure time and unpaid work. Value Health. 2018;21(12):1428–36.
66. Castro MC, Wilson ME, Bloom DE. Disease and economic burdens of
dengue. Lancet Infect Dis. 2017;17(3):e70–e8.
67. Andronis L, Maredza M, Petrou S. Measuring, valuing and including forgone
childhood education and leisure time costs in economic evaluation:
methods, challenges and the way forward. Soc Sci Med. 2019;237:112475.
68. Nyman JA. Cost recommendations in the second edition of cost-effectiveness
in health and medicine: a review. MDM Policy Pract. 2018;3(1):1–6.
69. Lakdawalla DN, Doshi JA, Garrison LP, Phelps CE, Basu A, Danzon PM.
Defining elements of value in health care—a health economics approach:
an ISPOR special task force report [3]. Value Health. 2018;21(2):131–9.
70. Gardner JW, Sanborn JS. Years of potential life lost (YPLL)—what does it
measure? Epidemiology. 1990;1:322–9.
71. World Health Organization. Making choice in health: WHO guide to cost
effective analysis. Geneva: WHO; 2003.
72. IHME. GBD Results Tools 2019. Available from: http://ghdx.healthdata.org/
gbd-results-tool.
73. Hung TM, Clapham HE, Bettis AA, Cuong HQ, Thwaites GE, Wills BA, et al.
The estimates of the health and economic burden of dengue in Vietnam.
Trends Parasitol. 2018;34(10):904–18.
74. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health
and medicine. New York: Oxford University Press; 1996.
75. Brouwer WB, Koopmanschap MA, Rutten FF. Productivity costs
measurement through quality of life? A response to the recommendation
of the Washington panel. Health Econ. 1997;6(3):253–9.
76. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW.
Methods for the economic evaluation of health care programmes, 4th edn.
New York: Oxford University Press; 2015.
77. Sculpher M. The role and estimation of productivity costs in economic
evaluation. In: Economic evaluation in health care: Merging theory with
practice. edn. Edited by Michael MD, Alistair McGuire. New York: Oxford
University Press; 2001. p. 94-112.
78. Olsen JA, Richardson J. Production gains from health care: what should be
included in cost-effectiveness analyses? Soc Sci Med. 1999;49(1):17–26.
79. Liljas B. How to calculate indirect costs in economic evaluations.
Pharmacoeconomics. 1998;13(1):1–7.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Hung et al. BMC Infectious Diseases          (2020) 20:393 Page 18 of 18
